Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUP NYSE:BHC NASDAQ:CARA NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsBHCBausch Health Cos$6.44+0.3%$5.53$3.96▼$9.85$2.38B0.412.55 million shs1.12 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,128 shs237,144 shsNVONovo Nordisk A/S$67.08-0.2%$70.36$57.00▼$139.74$300.14B0.647.36 million shs5.59 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos+1.26%-4.40%+6.65%+43.19%-12.36%CARACara Therapeutics0.00%0.00%0.00%0.00%+32.34%NVONovo Nordisk A/S-2.31%-3.31%-15.75%+7.06%-52.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos4.2229 of 5 stars1.94.00.04.02.33.31.9CARACara Therapeutics0.2844 of 5 stars0.00.00.04.20.60.80.0NVONovo Nordisk A/S4.2319 of 5 stars3.14.02.50.03.50.03.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ABHCBausch Health Cos 1.83Reduce$7.3013.34% UpsideCARACara Therapeutics 0.00N/AN/AN/ANVONovo Nordisk A/S 2.27Hold$112.0066.97% UpsideCurrent Analyst Ratings BreakdownLatest NVO, AUP, CARA, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/28/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/25/2025NVONovo Nordisk A/SDbs BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSell4/17/2025NVONovo Nordisk A/SGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/17/2025NVONovo Nordisk A/SBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00BHCBausch Health Cos$9.63B0.25$7.76 per share0.83($0.89) per share-7.24CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00NVONovo Nordisk A/S$42.12B7.11$3.89 per share17.23$4.66 per share14.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos-$46M-$0.11N/A1.38N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ANVONovo Nordisk A/S$14.64B$3.3819.8514.391.2934.52%80.94%24.23%8/6/2025 (Estimated)Latest NVO, AUP, CARA, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025 NVONovo Nordisk A/S$0.89N/AN/AN/A$77.51 billionN/A7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A5/7/2025Q1 2025NVONovo Nordisk A/S$0.92$0.92N/A$0.92N/A$11.87 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.642.44%N/A48.52%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02BHCBausch Health CosN/A1.350.97CARACara TherapeuticsN/A4.774.71NVONovo Nordisk A/S0.700.740.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos78.65%CARACara Therapeutics44.66%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos8.05%CARACara Therapeutics3.10%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableNVO, AUP, CARA, and BHC HeadlinesRecent News About These CompaniesHims & Hers hit with growing number of investor lawsuits after Novo deal exitJuly 16 at 5:02 PM | msn.com3 Ridiculously Discounted Growth Stocks to Buy NowJuly 16 at 10:55 AM | 247wallst.comAltman Advisors Inc. Grows Stake in Novo Nordisk A/S (NYSE:NVO)July 16 at 8:35 AM | marketbeat.comWhittier Trust Co. of Nevada Inc. Increases Position in Novo Nordisk A/S (NYSE:NVO)July 16 at 6:24 AM | marketbeat.comNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?July 16 at 6:14 AM | msn.comNVO Stock Bulls Have History on Their Side—Here’s How to Exploit ItJuly 16 at 6:14 AM | moneymorning.comMNovo Nordisk A/S (NYSE:NVO) Shares Bought by Apollon Wealth Management LLCJuly 16 at 5:59 AM | marketbeat.comNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?July 15 at 9:36 AM | zacks.comPAX Financial Group LLC Has $703,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)July 15 at 8:29 AM | marketbeat.comWest Family Investments Inc. Sells 4,502 Shares of Novo Nordisk A/S (NYSE:NVO)July 15 at 7:54 AM | marketbeat.comFolketrygdfondet Acquires 617,974 Shares of Novo Nordisk A/S (NYSE:NVO)July 15 at 7:14 AM | marketbeat.com8,473 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Hohimer Wealth Management LLCJuly 15 at 6:03 AM | marketbeat.com3 Absurdly Cheap Growth Stocks to Load Up On Right NowJuly 15 at 3:33 AM | fool.com3 Dividend Growth Stocks to Turn $10,000 Into $50,000 by 2035July 14 at 10:18 AM | 247wallst.comInvestors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to KnowJuly 14 at 10:00 AM | zacks.comOVERSEA CHINESE BANKING Corp Ltd Boosts Position in Novo Nordisk A/S (NYSE:NVO)July 14 at 8:23 AM | marketbeat.comSignaturefd LLC Cuts Stock Position in Novo Nordisk A/S (NYSE:NVO)July 14 at 7:15 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Stake Trimmed by Cutter & CO Brokerage Inc.July 14 at 6:51 AM | marketbeat.comTurtle Creek Wealth Advisors LLC Buys Shares of 10,532 Novo Nordisk A/S (NYSE:NVO)July 14 at 6:49 AM | marketbeat.comStephens Inc. AR Purchases 44,270 Shares of Novo Nordisk A/S (NYSE:NVO)July 14 at 5:33 AM | marketbeat.comSchechter Investment Advisors LLC Sells 11,403 Shares of Novo Nordisk A/S (NYSE:NVO)July 14 at 5:28 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVO, AUP, CARA, and BHC Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Bausch Health Cos NYSE:BHC$6.44 +0.02 (+0.33%) Closing price 03:59 PM EasternExtended Trading$6.41 -0.03 (-0.42%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Novo Nordisk A/S NYSE:NVO$67.08 -0.14 (-0.21%) Closing price 03:59 PM EasternExtended Trading$67.12 +0.05 (+0.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
